Belantamab Mafodotin
Modify Date: 2024-04-09 17:09:46
Belantamab Mafodotin structure
|
Common Name | Belantamab Mafodotin | ||
|---|---|---|---|---|
| CAS Number | 2050232-20-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Belantamab MafodotinBelantamab mafodotin (GSK2857916) is a humanized, afucosylated, anti-B-cell maturation antigen (BCMA) monoclonal antibody-drug conjugate (ADC) conjugated to MMAF (HY-15579) via a maleimidocaproyl linker (McMMAF, HY-15578). Belantamab mafodotin shows anti-myeloma activity[1][2]. |
| Name | Belantamab mafodotin |
|---|
| Description | Belantamab mafodotin (GSK2857916) is a humanized, afucosylated, anti-B-cell maturation antigen (BCMA) monoclonal antibody-drug conjugate (ADC) conjugated to MMAF (HY-15579) via a maleimidocaproyl linker (McMMAF, HY-15578). Belantamab mafodotin shows anti-myeloma activity[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Belantamab mafodotin binds to human BCMA protein with a Kd of 1 nM[2]. Belantamab mafodotin induces G2/M arrest in multiple myeloma cells in a dose and time dependent manner[2]. Belantamab mafodotin signifcantly promotes phagocytosis of multiple myeloma cells by human macrophages derived from macrophage colony-stimulating factor-stimulated monocytes[2]. |
| In Vivo | Belantamab mafodotin signifcantly improves survival compared to vehicle in mice harbouring OPM2 tumours[2]. Animal Model: Mice harbouring OPM2 tumours[2] Dosage: 4 mg/kg Administration: IP, twice weekly for 4 doses Result: Signifcantly improves survival compared to vehicle. |
| References |
[2]. Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613. |
| No Any Chemical & Physical Properties |